NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
Navigating Economic Resilience Through Life Sciences Investment
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
Driving Economic Transformation through Brain Health Investment in Africa